MUC1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism

Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with an unmet need for improved therapies. Responses to standard cytotoxic therapy in AML are often transient because of the emergence of chemotherapy‐resistant disease. The MUC1‐C oncoprotein governs critical pathways of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroopinsky, Dina, Rajabi, Hasan, Nahas, Myrna, Rosenblatt, Jacalyn, Rahimian, Maryam, Pyzer, Athalia, Tagde, Ashujit, Kharbanda, Akriti, Jain, Salvia, Kufe, Turner, Leaf, Rebecca K., Anastasiadou, Eleni, Bar‐Natan, Michal, Orr, Shira, Coll, Maxwell D., Palmer, Kristen, Ephraim, Adam, Cole, Leandra, Washington, Abigail, Kufe, Donald, Avigan, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050463/
https://www.ncbi.nlm.nih.gov/pubmed/29761849
http://dx.doi.org/10.1111/jcmm.13662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050463/
https://www.ncbi.nlm.nih.gov/pubmed/29761849
http://dx.doi.org/10.1111/jcmm.13662

Ejemplares similares